Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Jul 15, 2023; 15(7): 1262-1270
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Indicators | Control group (n = 30) | Research group (n = 32) | χ2/t | P value |
Age (years old) | 61.03 ± 6.91 | 61.44 ± 10.61 | 0.179 | 0.859 |
Gender (male/female) | 17/13 | 19/13 | 0.047 | 0.829 |
Clinical staging (II/III) | 18/12 | 16/16 | 0.625 | 0.429 |
Tumor diameter (cm) | 5.68 ± 1.29 | 5.80 ± 1.50 | 0.337 | 0.738 |
History of alcoholism (with/without) | 11/19 | 8/24 | 0.992 | 0.319 |
History of smoking (with/without) | 8/22 | 7/25 | 0.194 | 0.660 |
Family medical history (yes/no) | 5/25 | 9/23 | 1.163 | 0.281 |
- Citation: Zhang TW, Zhang P, Nie D, Che XY, Fu TT, Zhang Y. Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers. World J Gastrointest Oncol 2023; 15(7): 1262-1270
- URL: https://www.wjgnet.com/1948-5204/full/v15/i7/1262.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i7.1262